00:00Big news in biotech. Lyra Therapeutics, ticker, LYRA, just released promising results from its
00:06Enlightened 2 Phase 3 trial, and Wall Street is taking notice. LYRA 210, Lyra's long-acting
00:13sinus implant for chronic rhinosinusitis, showed statistically significant symptom relief at 24
00:19weeks. The treatment improved nasal obstruction, discharge, and facial pain with a p-value of 0.0078,
00:28a strong indicator of efficacy. Results were visible as early as week 4 and remained strong
00:34through week 24. Patients also saw better snot, 22 scores, measuring overall sinus health with a p-value
00:41of 0.0101. And safety, LYR 210 performed just as safely as the placebo, critical for regulatory
00:51approval. With a strong current ratio of 2.96, Lyra shows solid short-term liquidity even as it's
00:59still pre-profit. Investors are watching closely as LYRA positions itself as a potential game-changer
01:06in sinus treatment. Could FDA approval be next? Like, share, and follow for more biotech stock updates.
Comments